Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus HYDELTRASOL.
FLUDROCORTISONE ACETATE vs HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
0.1 mg orally once daily, range 0.05-0.2 mg/day
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Category D/X
Category C
Corticosteroid
Corticosteroid